JP2015509504A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509504A5 JP2015509504A5 JP2014558892A JP2014558892A JP2015509504A5 JP 2015509504 A5 JP2015509504 A5 JP 2015509504A5 JP 2014558892 A JP2014558892 A JP 2014558892A JP 2014558892 A JP2014558892 A JP 2014558892A JP 2015509504 A5 JP2015509504 A5 JP 2015509504A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- phe
- dmt
- lys
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 16
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 206010025135 lupus erythematosus Diseases 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 210000000214 mouth Anatomy 0.000 claims description 7
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 6
- 208000010201 Exanthema Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 206010022773 Intracranial pressure increased Diseases 0.000 claims description 6
- 208000000112 Myalgia Diseases 0.000 claims description 6
- 208000009525 Myocarditis Diseases 0.000 claims description 6
- 208000002151 Pleural effusion Diseases 0.000 claims description 6
- 206010036105 Polyneuropathy Diseases 0.000 claims description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 6
- 206010037394 Pulmonary haemorrhage Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 102000002262 Thromboplastin Human genes 0.000 claims description 6
- 108010000499 Thromboplastin Proteins 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 206010014665 endocarditis Diseases 0.000 claims description 6
- 201000005884 exanthem Diseases 0.000 claims description 6
- 208000018578 heart valve disease Diseases 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 208000013465 muscle pain Diseases 0.000 claims description 6
- 210000001331 nose Anatomy 0.000 claims description 6
- 208000008494 pericarditis Diseases 0.000 claims description 6
- 208000008423 pleurisy Diseases 0.000 claims description 6
- 230000007824 polyneuropathy Effects 0.000 claims description 6
- 230000002035 prolonged effect Effects 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 206010037844 rash Diseases 0.000 claims description 6
- 206010043554 thrombocytopenia Diseases 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 210000001635 urinary tract Anatomy 0.000 claims description 6
- 210000001215 vagina Anatomy 0.000 claims description 6
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 claims description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 5
- 201000009941 intracranial hypertension Diseases 0.000 claims description 5
- 201000003196 skeletal tuberculosis Diseases 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- 206010024648 Livedo reticularis Diseases 0.000 claims 2
- 206010057481 Lupus pneumonitis Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 1
- 159000000021 acetate salts Chemical group 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602418P | 2012-02-23 | 2012-02-23 | |
| US61/602,418 | 2012-02-23 | ||
| PCT/US2013/027430 WO2013126775A1 (en) | 2012-02-23 | 2013-02-22 | Aromatic-cationic peptides and uses of same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017235950A Division JP2018076337A (ja) | 2012-02-23 | 2017-12-08 | 芳香族陽イオン性ペプチドおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509504A JP2015509504A (ja) | 2015-03-30 |
| JP2015509504A5 true JP2015509504A5 (enExample) | 2016-04-14 |
Family
ID=49006261
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558892A Pending JP2015509504A (ja) | 2012-02-23 | 2013-02-22 | 芳香族陽イオン性ペプチドおよびその使用 |
| JP2017235950A Pending JP2018076337A (ja) | 2012-02-23 | 2017-12-08 | 芳香族陽イオン性ペプチドおよびその使用 |
| JP2019210301A Pending JP2020059720A (ja) | 2012-02-23 | 2019-11-21 | 芳香族陽イオン性ペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017235950A Pending JP2018076337A (ja) | 2012-02-23 | 2017-12-08 | 芳香族陽イオン性ペプチドおよびその使用 |
| JP2019210301A Pending JP2020059720A (ja) | 2012-02-23 | 2019-11-21 | 芳香族陽イオン性ペプチドおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10808008B2 (enExample) |
| EP (2) | EP3513800B1 (enExample) |
| JP (3) | JP2015509504A (enExample) |
| CN (1) | CN104203262A (enExample) |
| AU (3) | AU2013222237B2 (enExample) |
| CA (1) | CA2865409C (enExample) |
| WO (1) | WO2013126775A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836227A4 (en) * | 2012-04-12 | 2015-12-02 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| US9687519B2 (en) | 2013-03-01 | 2017-06-27 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention or treatment of barth syndrome |
| CA2916884C (en) * | 2013-03-01 | 2021-02-09 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial disease |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| WO2015084875A1 (en) * | 2013-12-02 | 2015-06-11 | Stealth Peptides International, Inc. | Compositions and methods for treating vitiligo |
| DE102015207415A1 (de) | 2015-04-23 | 2016-10-27 | Adidas Ag | Verfahren und Gerät zum Verknüpfen von Bildern in einem Video einer Aktivität einer Person mit einem Ereignis |
| WO2017117381A1 (en) * | 2015-12-31 | 2017-07-06 | Scott Duncan | Therapeutic compositions including peptides and uses thereof |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| CN107041946A (zh) * | 2017-03-24 | 2017-08-15 | 南京大学 | 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用 |
| CN107320711A (zh) * | 2017-03-24 | 2017-11-07 | 南京大学 | 化合物ss‑31在制备治疗弗里德赖希共济失调及相关疾病药物中的应用 |
| WO2020131282A1 (en) * | 2018-12-18 | 2020-06-25 | Stealth Biotherapeutics Corp. | Mitochondria-targeting peptides |
| CN115400201A (zh) * | 2021-05-26 | 2022-11-29 | 四川大学华西医院 | Ss-31在制备预防和/或治疗香烟诱导的气道炎症及慢性阻塞性肺疾病的药物中的用途 |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
| WO2025121297A1 (ja) * | 2023-12-08 | 2025-06-12 | サントリーホールディングス株式会社 | エネルギー代謝促進用組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| CA2554166C (en) * | 2004-01-23 | 2014-07-29 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| EP1799242A4 (en) * | 2004-09-16 | 2009-11-11 | Univ California | TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES |
| JP2009519033A (ja) * | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
| CN104056248A (zh) * | 2008-02-26 | 2014-09-24 | 康奈尔大学 | 用于防止和治疗急性肾损伤的方法 |
| CN106039282A (zh) | 2011-10-17 | 2016-10-26 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
-
2013
- 2013-02-22 WO PCT/US2013/027430 patent/WO2013126775A1/en not_active Ceased
- 2013-02-22 JP JP2014558892A patent/JP2015509504A/ja active Pending
- 2013-02-22 CN CN201380016624.6A patent/CN104203262A/zh active Pending
- 2013-02-22 EP EP18207640.6A patent/EP3513800B1/en active Active
- 2013-02-22 AU AU2013222237A patent/AU2013222237B2/en active Active
- 2013-02-22 CA CA2865409A patent/CA2865409C/en active Active
- 2013-02-22 US US14/380,484 patent/US10808008B2/en active Active
- 2013-02-22 EP EP13751525.0A patent/EP2817021B1/en active Active
-
2017
- 2017-12-08 JP JP2017235950A patent/JP2018076337A/ja active Pending
-
2018
- 2018-01-02 AU AU2018200000A patent/AU2018200000A1/en not_active Abandoned
-
2019
- 2019-09-17 AU AU2019232783A patent/AU2019232783B2/en active Active
- 2019-11-21 JP JP2019210301A patent/JP2020059720A/ja active Pending
-
2020
- 2020-10-07 US US17/064,937 patent/US20210261613A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509504A5 (enExample) | ||
| JP7548669B2 (ja) | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 | |
| JP2024075713A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| ES2941640T3 (es) | Moduladores de la actividad del complemento | |
| JP2020517719A (ja) | 睡眠時無呼吸を治療する方法及び組成物 | |
| JP2013535437A5 (enExample) | ||
| JP2007514750A5 (enExample) | ||
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2014523882A5 (enExample) | ||
| JP5973684B2 (ja) | 癌治療のための使用 | |
| JP2013501802A5 (enExample) | ||
| JP2010532761A5 (enExample) | ||
| CN1481256A (zh) | 一氧化氮的吸入 | |
| JP2007506752A (ja) | 肺動脈高血圧症を治療するための併用療法におけるイロプロスト | |
| AU2018260883A1 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
| WO2009099642A3 (en) | Proteomic analysis of active multiple sclerosis lesions | |
| JP2022121544A (ja) | 心肺血行動態を改善するための無機亜硝酸塩 | |
| JP2005532321A (ja) | 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物 | |
| JP2020516689A5 (enExample) | ||
| JP2003040797A (ja) | 抗炎症性肺疾患およびａｒｄｓにおける抗トロンビン吸入のための医薬製剤 | |
| RU2009141168A (ru) | Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна | |
| JP2005533062A (ja) | キセノン含有ガスによる脳保護 | |
| JP2021510157A (ja) | 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用 | |
| JPWO2019183463A5 (enExample) |